Table 5.
Blood Chemistry Data. Data are presented as mean ± standard deviation
| Variable | Treatment | PRE | Week 8 | POST | Reference Interval | p |
|---|---|---|---|---|---|---|
| Serum Glucose (mg/dL) | PLA | 90.5 ± 11.0 | 89.3 ± 3.6 | 90.2 ± 5.4 | 65–99 | 0.84 |
| TRT | 88.8 ± 6.1 | 89.6 ± 7.0 | 90.0 ± 6.8 | |||
| BUN (mg/dL) | PLA | 17.3 ± 4.9 | 17.8 ± 3.9 | 17.5 ± 4.2 | 6–20 | 0.98 |
| TRT | 15.1 ± 3.2 | 15.7 ± 3.1 | 15.7 ± 3.5 | |||
| Serum Creatinine (mg/dL) | PLA | 0.97 ± 0.12 | 1.04 ± 0.12a | 1.13 ± 0.17*ab | 0.76–1.27 | 0.001 |
| TRT | 1.05 ± 0.15 | 1.10 ± 0.11 | 1.05 ± 0.12*‡ | |||
| eGFR (mL/min/1.73) | PLA | 105.6 ± 12.9 | 98.7 ± 12.5a | 91.0 ± 14.9a | >59 | 0.01 |
| TRT | 101.0 ± 15.8 | 95.2 ± 11.1 | 100.3 ± 12.9*‡ | |||
| BUN/Creatinine Ratio | PLA | 18.0 ± 5.9 | 17.3 ± 4.0 | 15.8 ± 4.4 | 8–19 | 0.33 |
| TRT | 14.4 ± 3.1 | 14.3 ± 1.8 | 15.0 ± 3.7 | |||
| Serum Sodium (mmol/L) | PLA | 138.8 ± 1.8 | 139.6 ± 1.3 | 140.4 ± 2.1 | 134–144 | 0.43 |
| TRT | 138.9 ± 1.7 | 138.7 ± 1.3 | 140.4 ± 1.3 | |||
| Serum Potassium (mmol/L) | PLA | 4.4 ± 0.4 | 4.5 ± 0.5 | 4.3 ± 0.3 | 3.5–5.2 | 0.06 |
| TRT | 4.4 ± 0.3 | 4.4 ± 0.3 | 4.6 ± 0.3 | |||
| Serum Chloride (mmol/L) | PLA | 102.1 ± 1.6 | 101.0 ± 1.4 | 102.4 ± 2.2 | 97–108 | 0.92 |
| TRT | 101.7 ± 1.8 | 100.7 ± 2.1 | 102.3 ± 1.6 | |||
| Carbon Dioxide (mmol/L) | PLA | 23.6 ± 2.4 | 22.1 ± 1.5 | 22.5 ± 1.5 | 19–28 | 0.24 |
| TRT | 23.1 ± 2.4 | 21.0 ± 1.2 | 22.8 ± 1.4 | |||
| Serum Calcium (mg/dL) | PLA | 9.4 ± 0.4 | 9.4 ± 0.3 | 9.3 ± 0.3 | 8.7–10.2 | 0.45 |
| TRT | 9.6 ± 0.4 | 9.5 ± 0.3 | 9.4 ± 0.4 | |||
| Serum Protein (g/dL) | PLA | 7.1 ± 0.3 | 6.9 ± 0.3 | 6.9 ± 0.3 | 6.0–8.5 | 0.58 |
| TRT | 7.2 ± 0.3 | 6.9 ± 0.2 | 6.9 ± 0.3 | |||
| Serum Albumin (g/dL) | PLA | 4.4 ± 0.3 | 4.6 ± 0.2 | 4.6 ± 0.2 | 3.5–5.5 | 0.65 |
| TRT | 4.5 ± 0.2 | 4.6 ± 0.2 | 4.6 ± 0.2 | |||
| Globulin (g/dL) | PLA | 2.6 ± 0.2 | 2.3 ± 0.2 | 2.3 ± 0.2 | 1.5–4.5 | 0.83 |
| TRT | 2.7 ± 0.2 | 2.3 ± 0.3 | 2.3 ± 0.3 | |||
| Albumin:Globulin Ratio | PLA | 1.7 ± 0.2 | 2.0 ± 0.2 | 2.0 ± 0.3 | 1.1–2.5 | 0.76 |
| TRT | 1.7 ± 0.2 | 2.0 ± 0.3 | 2.1 ± 0.3 | |||
| Bilirubin (mg/dl) | PLA | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.6 ± 0.2 | 0.0–1.2 | 0.06 |
| TRT | 0.6 ± 0.3 | 0.7 ± 0.4 | 0.5 ± 0.2 | |||
| Alkaline Phosphatase (IU/L) | PLA | 76.4 ± 13.8 | 81.3 ± 14.6 | 79.9 ± 16.1 | 39–117 | 0.53 |
| TRT | 70.5 ± 20.8 | 79.5 ± 27.2 | 77.8 ± 23.4 | |||
| AST (IU/L) | PLA | 25.5 ± 7.8 | 26.9 ± 7.4 | 25.8 ± 8.9 | 0–40 | 0.81 |
| TRT | 25.1 ± 7.5 | 28.9 ± 11.6 | 27.2 ± 12.7 | |||
| ALT (IU/L) | PLA | 23.7 ± 4.9 | 24.3 ± 7.0 | 22.5 ± 6.3 | 0–44 | 0.48 |
| TRT | 23.5 ± 11.1 | 23.3 ± 8.6 | 26.5 ± 12.2 |
*indicates significantly different from PLA at the corresponding time point. ‡ indicates significantly different from PLA at week 8. The p-value is derived from an ANOVA and representative of a main effect for group by time. Significant within-group time differences are indicated by a(different from pre) and b(different from week 8) for variables with a significant group x time interaction